Terminology Service for NFDI4Health
All terms in BAO
| Label | Id | Description |
|---|---|---|
| ovarian disease | DOID_1100 | |
| EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor | CHEBI_63721 | |
| EC 2.1.2.* (hydroxymethyl-, formyl- and related transferases) inhibitor | CHEBI_76874 | |
| EC 2.1.1.45 (thymidylate synthase) inhibitor | CHEBI_63720 | |
| EC 2.1.1.* (methyltransferases) inhibitor | CHEBI_76871 | |
| salpingo-oophoritis | DOID_10972 | |
| salpingitis | DOID_5733 | |
| acute salpingitis | DOID_10973 | |
| spastic quadriplegia | DOID_10970 | [A spastic cerebral palsy that affects all four limbs. The individuals have difficulty with walking and talking.] |
| neuroprotective agent | CHEBI_63726 | |
| protective agent | CHEBI_50267 | |
| antibiotic resistance | BAO_0000099 | [It is the quality which allows a microorganism to survive after exposure to one or more antibiotics.] |
| cellular quality | PATO_0001396 | [A monadic quality of continuant that exists at the cellular level of organisation.] |
| screening concentration | BAO_0000098 | [The concentration of a perturbagen used in an assay to elicit the biological effect or perturbation. This typically assumes uniform / equal distribution of the perturbagen / compound in the assay system (typically a screening well).] |
| membranous glomerulonephritis | DOID_10976 | |
| glomerulonephritis | DOID_2921 | [A nephritis that causes inflammation of the glomeruli located_in kidney.] |
| percent growth inhibition | BAO_0000096 | [% growth reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay.] |
| two-colour indicator | CHEBI_50412 | |
| colour indicator | CHEBI_50410 | |
| visual indicator | CHEBI_50408 |